Leerink Partnrs Issues Positive Outlook for MIRM Earnings

Key Points

• Leerink Partners raised its Q3 2025 earnings per share (EPS) estimate for Mirum Pharmaceuticals from ($0.39) to ($0.18), signaling a more optimistic outlook for the company.
• Several analysts have upgraded their ratings on Mirum Pharmaceuticals, with a consensus rating of "Buy" and a target price ranging from $72.00 to $89.00.
• Mirum Pharmaceuticals reported a revenue of $127.79 million for the last quarter, exceeding expectations and reflecting a 64.1% increase compared to the same quarter last year.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of Mirum Pharmaceuticals in a report released on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.39). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals' Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $2.10 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The business had revenue of $127.79 million for the quarter, compared to the consensus estimate of $107.91 million. During the same period in the prior year, the firm earned ($0.52) earnings per share. The company's revenue was up 64.1% compared to the same quarter last year.

Several other brokerages have also recently issued reports on MIRM. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 7th. HC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Stifel Nicolaus set a $89.00 target price on shares of Mirum Pharmaceuticals and gave the stock a "buy" rating in a report on Monday. JMP Securities set a $81.00 target price on shares of Mirum Pharmaceuticals and gave the stock a "market outperform" rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of "Buy" and an average target price of $74.13.

Mirum Pharmaceuticals Trading Down 1.7%

Shares of Mirum Pharmaceuticals stock traded down $1.15 during trading on Monday, reaching $64.72. The company's stock had a trading volume of 1,380,291 shares, compared to its average volume of 490,700. Mirum Pharmaceuticals has a 52-week low of $36.86 and a 52-week high of $67.45. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -53.49 and a beta of 0.94. The firm's 50-day moving average is $51.26 and its two-hundred day moving average is $47.30. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently modified their holdings of the business. CWM LLC increased its holdings in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after purchasing an additional 428 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $35,000. Comerica Bank grew its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after buying an additional 278 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $42,000. Finally, Quarry LP acquired a new stake in Mirum Pharmaceuticals in the first quarter valued at $56,000.

Insider Activity at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 10,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the transaction, the senior vice president directly owned 2,426 shares in the company, valued at approximately $140,708. This trade represents a 80.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $55.25, for a total value of $2,210,000.00. Following the completion of the sale, the chief executive officer owned 138,641 shares of the company's stock, valued at $7,659,915.25. This trade represents a 22.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,041 shares of company stock valued at $2,840,624. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.